Zogenix, Inc.

335 articles about Zogenix, Inc.

• Zogenix Reports Granting of Inducement Awards

  9/16/2021

  Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen (14) new employees.

• Zogenix Reports Granting of Inducement Awards - Aug 16, 2021

  8/16/2021

  Zogenix announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen new employees.

• Zogenix Provides Corporate Update and Reports Second Quarter 2021 Financial Results

  8/5/2021

  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results for the three and six months ended June 30, 2021, and provided a corporate update.

• Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference

  8/3/2021

  Zogenix, a global biopharmaceutical company developing and commercializing rare disease therapies, announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Chief Financial Officer, will participate in a virtual fireside chat on Tuesday, August 10, 2021, at the BofA SMID Cap 2H21 Ideas Conference.

• VIP Siblings and www.vipsibling.com, New Resources to Support Brothers & Sisters of Those Living with Severe, Rare Epilepsies, Now Available from Zogenix and 10 Advocacy Groups

  7/14/2021

  Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups announced the launch of VIP Siblings, a new website and suite of materials created to celebrate and deepen support for siblings of adolescents living with rare and severe forms of epilepsy.

• Zogenix to Participate in Two Upcoming Investor Conferences - June 21, 2021

  6/21/2021

  Zogenix, a global biopharmaceutical company developing and commercializing rare disease therapies, announced that members of its management team will participate in two upcoming investor conferences: the Raymond James Human Health Innovation Conference and SVB Leerink CNS Forum.

• Zogenix Launches Dravet Syndrome Community Photo Sharing Charitable Campaign and Contest to Benefit the Dravet Syndrome Foundation and the Epilepsy Foundation

  5/19/2021

  - Zogenix, a global biopharmaceutical company developing rare disease therapies, today launched the FINTEPLA Photo Diary, a community sharing, charitable campaign and contest.

• Zogenix to Participate in the BofA Securities 2021 Healthcare Conference

  5/11/2021

  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a virtual fireside chat on Thursday, May 13, 2021, at the BofA Securities 2021 Healthcare Conference.

• Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results

  5/6/2021

  Zogenix, a global biopharmaceutical company developing and commercializing rare disease therapies, announced financial results for the three months ended March 31, 2021, and provided a corporate update.

• Zogenix Launches Global Access Program for FINTEPLA® (Fenfluramine) Oral Solution

  4/27/2021

  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced the launch of its new global access program for FINTEPLA (fenfluramine) oral solution.

• Zogenix to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 6

  4/22/2021

  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the first quarter ended March 31, 2021 and host a corporate update conference call and webcast after the market close on Thursday, May 6, 2021, at 4:30 PM Eastern Time.  

• Zogenix Presents New Data at Virtual AAN 2021 Showing Improved Executive Function in Lennox-Gastaut Syndrome (LGS) Patients Treated with FINTEPLA® (Fenfluramine) Oral Solution

  4/22/2021

  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new data showing the positive impact of treatment with FINTEPLA® (fenfluramine) oral solution on everyday executive function for children and young adults with Lennox-Gastaut syndrome (LGS).

• Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients, Caregivers, and Families at Virtual AAN 2021

  4/16/2021

  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new findings from an investigator-initiated study designed to assess caregivers’ perspectives on the long-term seizure- and non-seizure-related benefits of FINTEPLA®

• Zogenix to Participate in the 20th Annual Needham Virtual Healthcare Conference

  4/8/2021

  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat on Monday, April 12, 2021, at the 20th Annual Needham Virtual Healthcare Conference.

• Zogenix to Participate in the Stifel 3rd Annual CNS Day

  3/25/2021

  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat on Wednesday, March 31, 2021, at the Stifel 3 rd Annual CNS Day.

• Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

  2/18/2021

  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Friday, February 26, 2021, at the 10th Annual SVB Leerink Global Healthcare Conference.

• Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25

  2/11/2021

  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2020 and host a corporate update conference call and webcast after the market close, on Thursday, February 25, 2021, at 4:30 PM Eastern Time.

• Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution Now Available in Germany for the Treatment of Seizures in Dravet Syndrome

  2/1/2021

  FINTEPLA offers a new treatment option for patients in Germany with Dravet syndrome, a rare, devastating, infant-onset epilepsy marked by frequent seizures, medical emergencies, and developmental impairments

• Zogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020

  12/1/2020

  New long-term safety, efficacy, and durability data for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome Full results from Phase 3 study of FINTEPLA in Lennox-Gastaut syndrome New d ata from investigator-initiated stud y in CDKL5 Deficiency Disorder

• Zogenix to Participate in the Stifel 2020 Virtual Healthcare Conference

  11/11/2020

  Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, and Treasurer, will participate in a fireside chat on Wednesday, November 18, 2020, at the Stifel 2020 Virtual Healthcare Conference.